SOURCE: Wall Street News Alert

Wall Street News Alert

January 10, 2008 09:48 ET

Wall Street News Alert: BOCX Is on the Move! January 10, 2008

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by Wall Street Capital Funding.

WESTON, FL--(Marketwire - January 10, 2008) - Wall Street News Alert's "stocks to watch" this morning are: BioCurex (OTCBB: BOCX), Merck & Co., Inc. (NYSE: MRK), Amgen (NASDAQ: AMGN) and Genzyme Corp. (NASDAQ: GENZ).

BioCurex (OTCBB: BOCX) continues to issue positive news this week, and investors are urged to keep watching the company this morning. Yesterday after the markets closed, the biotechnology company with patented/proprietary technology identifying a cancer marker, RECAF, and Inverness Medical Innovations announced a licensing agreement for BioCurex's RECAF™ material and technology.

This should be great news for the company, as the press release states that more than three years of testing by BioCurex has confirmed RECAF's high degree of clinical sensitivity and specificity in detecting various types of cancer, even when the disease is at its earliest stage. RECAF (the receptor for alpha-fetoprotein) is a wide-spectrum marker present in malignant cancer cells and absent in most normal cells, allowing it to play a major role in the development of new diagnostic tests for prostate, breast, colorectal, lung and other cancers.

Under terms of the license agreement, Inverness Medical Innovations will obtain semi-exclusive worldwide rights to commercialize products using this technology. BioCurex will be paid up-front fees, product and development milestones, plus royalties on product sales.

According to the World Health Organization, more than 10 million people are diagnosed with cancer every year, and this number is expected to reach 15 million in a dozen years. The RECAF technology becomes hugely significant when considering that the chance of a cure increases substantially if the disease is detected early (i.e. the five-year survival rate for breast cancer ranges from 87% at Stage 1 to only 13% at Stage IV). Cancer screening and recurrent evaluations are anticipated diagnostic applications for the RECAF cancer marker.

Wall Street News Alert is alerting investors to monitor the progress of the BioCurex! "BioCurex's RECAF technology has the potential to revolutionize cancer detection by differentiating malignant cells from healthy ones. For this reason, we are delighted to be partnering with one of the world's leading developer/manufacturers of advanced diagnostic products. With major facilities in the U.S., Europe and Asia, Inverness Medical Innovations has an impressive reputation for aggressive and innovative consumer marketing. We are especially looking forward to working with them on expanding and implementing our RECAF technology on future cancer tests,'' said Ricardo Moro, M.D., BioCurex's CEO.

Prior to the latest press release, the stock closed Wednesday at Seventy cents a share.

To view all of Wall Street News Alert's special early morning trading alerts for this morning, visit, where you may also sign up to receive free email alerts in advance of our press releases being issued.

In case you are not familiar with the companies: BioCurex, Inc. is a biotechnology company that is developing products based on patented/proprietary technology for cancer diagnosis and therapy. The core technology identifies a cancer marker known as RECAF, found only on malignant cells in a variety of cancers, but absent in normal and most benign cells. BioCurex is also working on further methods for cancer detection and cancer treatment.

By developing new capabilities in near-patient diagnosis, monitoring and health management, Inverness Medical Innovations enables individuals to take charge of improving their health and quality of life. A global leader in rapid point-of-care diagnostics, Inverness' products, as well as its new product development efforts, focus on infectious disease, cardiology, oncology, drugs of abuse and women's health.

Merck & Co., Inc. (NYSE: MRK) up 1.4% on 16.7 million shares traded.

Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs.

Amgen (NASDAQ: AMGN) up 2.8% on 12 million shares traded.

Amgen discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses.

Genzyme Corp. (NASDAQ: GENZ) up 2.4% on 4.8 million shares traded.

One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 10,000 employees in locations spanning the globe and 2007 revenues of $3.8 billion. In 2007, Genzyme was chosen to receive the National Medal of Technology, the highest honor awarded by the President of the United States for technological innovation.

Market Commentary:

"Gasoline inventories surpassed analysts' expectations, rising sharply by 5.3 million barrels, or 2.6 percent, to 213.1 million barrels. They forecasted stockpiles would climb by only 1.6 million barrels last week," stated Sonja Rudd in Wall Street News Alert's daily commentary continued at:

Let Wall Street News Alert help advertise for your company using our effective awareness campaigns. If you're interested in telling your story, we can help. Contact us at or see our services at

WSNA's email alert service is free to those investors who sign up on the WSNA home page. The alert service is designed to notify investors of undervalued and often overlooked stocks. Subscribers are introduced to Special Situation companies that have the potential of showing increased activity. The Wall Street News Alert home page has experienced over 100 million hits. To subscribe to this free service, visit the Wall Street News Alert home page at and select the "join now" button.

*** It has come to the attention of Wall Street News Alert (WSNA), that various persons or companies distribute faxes bearing similar names to Wall Street News Alert. Wall Street News Alert is not affiliated with faxes bearing names such as: Wall Street Stock Alert, Wall Street Investor Alert, Wall Street News Alert or any other fax using various combinations of the generic words Wall Street.***

Wall Street News Alert is a division of Wall Street Capital Funding LLC (WSCF). WSCF also maintains a contractual, working relationship with Stock Market Alerts LLC and its Wall Street Enews brand. WSCF is not a registered broker/dealer and may not sell, offer to sell or offer to buy any security. WSCF profiles are not a solicitation or recommendation to buy, sell or hold securities. An offer to buy or sell can be made only with accompanying disclosure documents from the company offering or selling securities and only in the states and provinces for which they are approved. The material in this release is intended to be strictly informational. The companies that are discussed in this release have not approved the statements made in this release nor approved the timing of this release. All statements and expressions are the sole opinion of WSCF and are subject to change without notice. Information in this release is derived from a variety of sources including that company's publicly disseminated information, third parties and WSCF research. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. WSCF disclaims any and all liability as to the completeness or accuracy of the information contained and any omissions of material fact in this release. The release may contain technical inaccuracies or typographical errors. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. Investment in the securities of the companies discussed in this release is highly speculative and carries a high degree of risk. WSCF is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment if they make a purchase in WSCF profiled stocks.

This profile is not without bias, and is a paid release. WSCF has been compensated for dissemination of company information on behalf of one or more of the companies mentioned in this release. WSCF has been compensated Eleven Thousand and Five Hundred Dollars for coverage of BioCurex (OTCBB: BOCX), by a third party, Onyx Consulting Group LLC., who is non-affiliated and may hold significant positions in the stock, for services provided including dissemination of company information in this release. WSCF holds no shares of the stock. WSCF may receive additional compensation for extension of its services. Any additional compensation will be disclosed at such time that WSCF is aware of a client's desire to extend the original services. WSCF may have received shares of a company profiled in this release prior to the dissemination of the information in this release. WSCF may immediately sell some or any shares in a profiled company held by WSCF and may have previously sold shares in a profiled company held by WSCF. WSCF's services for a company may cause the company's stock price to increase, in which event WSCF would make a profit when it sells its stock in a company. In addition, WSCF's selling of a company's stock may have a negative effect on the market price of the stock.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may," "future," "plan" or "planned," "will" or "should," "expected," "anticipates," "draft," "eventually" or "projected." You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and WSCF undertakes no obligation to update such statements.

Contact Information